Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: exendin 9-39 Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus

NCT02170870
View directory record Official record
Conditions
Dyspepsia, Diabetes Mellitus With Gastrointestinal Symptoms
Interventions
Exendin 9-39, Microlipid, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of DPP4 Inhibition on Growth Hormone Secretion

NCT01701973
View directory record Official record
Conditions
Obesity
Interventions
Sitagliptin, Pegvisomant, Placebo, L-NMMA, Exendin 9-39
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Early Phase 1 Interventional

Determinants of Diabetes Remission After Gastric Bypass Surgery

NCT02287285
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exendin9
Drug
Lead sponsor
Blandine Laferrere
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Results available

Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia

NCT04652479
View directory record Official record
Conditions
Acquired Hyperinsulinemic Hypoglycemia
Interventions
Avexitide
Drug
Lead sponsor
Dr. Tracey McLaughlin, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 18, 2026, 12:34 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

NCT06972407
View directory record Official record
Conditions
Genetic Predisposition, Type2diabetes
Interventions
Exendin 9-39, Saline
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

NCT00897676
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), placebo
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia

NCT02771574
View directory record Official record
Conditions
Post Bariatric Hypoglycemia
Interventions
Lyo avexitide, Liq avexitide
Drug
Lead sponsor
Tracey McLaughlin
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 18, 2026, 12:34 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

NCT01803451
View directory record Official record
Conditions
Post-bariatric Surgery
Interventions
exendin -(9-39)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 18, 2026, 12:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

NCT00835328
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin (9-39), Vehicle
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
Up to 12 Months
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 18, 2026, 12:34 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

NCT06967558
View directory record Official record
Conditions
PreDiabetes
Interventions
Exendin 9-39, Saline
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass

NCT01843881
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exendin 9, 39, Placebo
Drug
Lead sponsor
Adrian Vella
Other
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

NCT03373435
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
exendin 9-39, Placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

NCT01795144
View directory record Official record
Conditions
Monogenic Diabetes
Interventions
GLP-1, Exendin 9-39
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 18, 2026, 12:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Ghrelin Effect on Beta Cell Function in Health and Disease

NCT01729299
View directory record Official record
Conditions
Diabetes
Interventions
Exendin (9-39), acyl ghrelin, saline
Drug
Lead sponsor
David Dalessio
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Effects of GLP-1 Receptor Activation

NCT03101930
View directory record Official record
Conditions
Obesity, PreDiabetes
Interventions
Liraglutide, Sitagliptin, hypocaloric diet, Placebos, Exendin (9-39)
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

NCT00571324
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
7 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 18, 2026, 12:34 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Regulation of Insulin Secretion by the GLP-1 Receptor

NCT02844907
View directory record Official record
Conditions
Insulin Secretion
Interventions
Exendin (9-39), Dexamethasone, Hyperglycemic Clamp
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 18, 2026, 12:34 PM EDT
Available No phase listed Expanded access

An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia

NCT07582874
View directory record Official record
Conditions
Post-bariatric Hypoglycemia
Interventions
Avexitide
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
U.S. locations
4
States / cities
Boston, Massachusetts • Morehead City, North Carolina • Mesquite, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 18, 2026, 12:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of GLP-1 on Postprandial Lipid Metabolism

NCT01760772
View directory record Official record
Conditions
Heart Disease
Interventions
Exendin-9, GLP-1, saline
Drug · Other
Lead sponsor
David Dalessio
Other
Eligibility
40 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 18, 2026, 12:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

NCT02550145
View directory record Official record
Conditions
Hypoglycemia
Interventions
Exendin (9-39), Placebo
Drug · Other
Lead sponsor
Tracey McLaughlin
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 18, 2026, 12:34 PM EDT
Withdrawn Phase 2 Interventional

Mechanisms Underlying Predictors of Success From Obesity Surgery

NCT02697253
View directory record Official record
Conditions
Obesity
Interventions
Exendin 9-39 and Sitagliptin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glucagon Regulation of Glucose Metabolism

NCT04347252
View directory record Official record
Conditions
Insulin Secretion
Interventions
Glucagon
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 18, 2026, 12:34 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Bariatric Surgeries on Glucose Metabolism

NCT02823665
View directory record Official record
Conditions
Post Bariatric Surgery, Gastric Bypass, Sleeve Gastrectomy, Hypoglycemia After Gastric Bypass
Interventions
Exendin-(9-39), Atropine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Not applicable Interventional Results available

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

NCT01162499
View directory record Official record
Conditions
Postprandial Hypoglycemia
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 18, 2026, 12:34 PM EDT